drugset / Trial / NCT04230408
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
Phase 2
Completed
48 enrolled
Latin American Cooperative Oncology Group
AstraZeneca · collabLibbs Farmacêutica LTDA · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study that will assess if Durvalumab (MEDI4736) used as induction chemo-immunotherapy followed by concurrent chemo-immuno-radiotherapy and consolidation immunotherapy may improve oncologic outcomes compared with standard of care chemoradiation followed by durvalumab (as in the PACIFIC trial) with a reasonable safety profile.
Timeline
- Start
- 2021-03-05
- Primary completion
- 2024-10-07
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | Intravenous |